Testing how well PF-07941944 is tolerated in healthy adults
Official title: A Multipart Phase 1 Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study With Single and Multiple Dose Escalation to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-07941944 in Healthy Adult Participants
Run by Pfizer · NCT06920498 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing how well a new medicine called PF-07941944 is tolerated by healthy adults to see if it is safe for use.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Pfizer Industry-sponsored |
| Locations | 1 site (Brussels, Bruxelles-capitale, Région DE) |
| Trial ID | NCT06920498 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy males and females aged 18 to 60 with a BMI between 17.5 and 30.5 kg/m2.
✕Probably not a fit
Patients with significant medical or psychiatric conditions, or those taking certain medications, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the safety and tolerability of the investigational medicine PF-07941944 in healthy adult participants. The study will involve administering different amounts of the medication and comparing the experiences of those receiving the drug to those receiving a placebo. Participants will be monitored over a period of approximately 4 months for Part 1 and 2.5 months for Parts 2 and 3, with regular study visits and follow-up calls to assess their health and any side effects.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the safety profile of PF-07941944, potentially leading to new treatments for respiratory syncytial virus (RSV).
How similar studies have gone: While this study focuses on a specific investigational drug, similar studies assessing the safety of new medications in healthy participants have shown success in the past.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) of 17.5 to 30.5 kg/m2 * For inclusion of Japanese participants: participants who have 4 Japanese biologic grandparents who were born in Japan. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation * Use of prescription or nonprescription drugs and dietary and herbal supplements within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention. * Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). * History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. * Part 3 only: History of acute narrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, respiratory insufficiency, myasthenia gravis, or adverse reaction to midazolam or other benzodiazepines. History of hypersensitivity reaction to midazolam, or any of the formulation components.
Where it's running
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région DE, Belgium Recruiting
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How age affects germinal center responses after flu and rabies vaccines
Researchers will test how the immune system responds to flu and rabies vaccines in younger adults (18–40) and older adults (65+).
-
Magnetic field maps with NV sensors for non-invasive heart measurements
This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.
-
Methylation analyses using home-based self-sampling in women with and without gynecological disease
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation markers that distinguish people with gynecological (pre-)cancers from cancer-free controls.
-
Omega-3 status in healthy adults: comparing different fish-oil and algae-oil products
This study tests whether various fish-oil and algae-oil products can raise the Omega-3 Index in healthy adults who don’t eat much fatty fish.
-
A safe, carefully dosed test of TBD11 in healthy adults
This phase 1 study tests TBD11 in healthy adults to see if it is safe and tolerable and to understand how it behaves in the body, including how it interacts with other medicines.
-
Fosmanogepix in healthy adults: how it may interact with other drugs and heart rhythm
This study tests whether fosmanogepix (and its active form manogepix) changes how other medicines work in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.